Search

Your search keyword '"Venat-Bouvet, L"' showing total 174 results

Search Constraints

Start Over You searched for: Author "Venat-Bouvet, L" Remove constraint Author: "Venat-Bouvet, L"
174 results on '"Venat-Bouvet, L"'

Search Results

1. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

3. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

6. 131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study

7. 59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study

8. Valeur pronostique de la cinétique précoce de l’ADN tumoral circulant en cours de chimiothérapie néoadjuvante pour les patientes présentant un cancer épithélial de l’ovaire à un stade avancé. Résultats préliminaires d’une analyse ancillaire de l’étude de phase II CHIVA (ARCAGY-GINECO)

9. 1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

10. 260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)

11. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

12. Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’

13. 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study

14. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

15. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

16. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

17. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

18. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

19. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

20. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

21. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

24. 829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial

25. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

26. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

27. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

28. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

29. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

30. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

31. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

32. Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

33. Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

34. Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: A GINECO study

35. Abstract GS2-07: PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

36. Increased incidence of pathogenic variants in ATMin the context of testing for breast and ovarian cancer predisposition

37. Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study.

38. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

39. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

40. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

41. 5-years RFS and prognostic factors study in HR-positive HER2-negative breast cancer patients treated with neoadjuvant endocrine therapy : Pooled analysis of two phase II trials

42. Abstract P3-13-02: Withdrawn

43. Abstract P3-12-10: First 6-month report of the longitudinal PHACS study (Pharmacology and Hormonotherapy (HT) for Adjuvant breast Cancer (BC) Study, NCT01127295)

44. Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

45. Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial

49. 1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

50. The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome

Catalog

Books, media, physical & digital resources